Washington University School of Medicine

Digital Commons@Becker
2020-Current year OA Pubs

Open Access Publications

7-1-2022

Performance of a multianalyte 'rule-out' assay in pregnant
individuals with suspected preeclampsia
Maged M Costantine
The Ohio State University

Georges Macones
Washington University School of Medicine in St. Louis

et al

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4
Part of the Medicine and Health Sciences Commons

Recommended Citation
Costantine, Maged M; Macones, Georges; and et al, "Performance of a multianalyte 'rule-out' assay in
pregnant individuals with suspected preeclampsia." Hypertension. 79, 7. 1515 - 1524. (2022).
https://digitalcommons.wustl.edu/oa_4/237

This Open Access Publication is brought to you for free and open access by the Open Access Publications at
Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized
administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Hypertension
ORIGINAL ARTICLE

Performance of a Multianalyte ‘Rule-Out’
Assay in Pregnant Individuals With Suspected
Preeclampsia
Maged M. Costantine , Baha Sibai, Allan T. Bombard, Mark Sarno, Holly West, David M. Haas , Alan T. Tita, Michael J. Paidas,
Erin A.S. Clark, Kim Boggess, Chad Grotegut , William Grobman, Emily J Su , Irina Burd, George Saade, Martin R. Chavez ,
Michael J. Paglia, Audrey Merriam, Carlos Torres, Mounira Habli , Georges Macones, Tony Wen , James Bofill, Anna Palatnik,
Rodney K. Edwards, Sina Haeri, Pankaj Oberoi, Amin Mazloom, Matthew Cooper, Steven Lockton, Gary D. Hankins
BACKGROUND: The ability to diagnose preeclampsia clinically is suboptimal. Our objective was to validate a novel multianalyte
assay and characterize its performance, when intended for use as an aid to rule-out preeclampsia.
METHODS: Prospective, multicenter cohort study of pregnant individuals presenting between 280/7 and 366/7 weeks’ with
preeclampsia-associated signs and symptoms. Individuals not diagnosed with preeclampsia after baseline evaluation were
enrolled in the study cohort, with those who later developed preeclampsia, classified as cases and compared with a negative
control group who did not develop preeclampsia. Individuals with assay values at time of enrollment ≥0.0325, determined
using a previously developed algorithm, considered at risk. The primary analysis was the time to develop preeclampsia
assessed using a multivariate Cox regression model.
Downloaded from http://ahajournals.org by on September 14, 2022

RESULTS: One thousand thirty-six pregnant individuals were enrolled in the study cohort with an incidence of
preeclampsia of 30.3% (27.6%–33.2%). The time to develop preeclampsia was shorter for those with an at-risk
compared with negative assay result (log-rank P<0.0001; adjusted hazard ratio of 4.81 [3.69–6.27, P<0.0001]).
The performance metrics for the assay to rule-out preeclampsia within 7 days of enrollment showed a sensitivity
76.4% (67.5%–83.5%), negative predictive value 95.0% (92.8%–96.6%), and negative likelihood ratio 0.46 (0.32–
0.65). Assay performance improved if delivery occurred <37 weeks and for individuals enrolled between 28 and
35 weeks.
CONCLUSIONS: We confirmed that a novel multianalyte assay was associated with the time to develop preeclampsia and has
a moderate sensitivity and negative likelihood ratio but high negative predictive value when assessed as an aid to rule out
preeclampsia within 7 days of enrollment.
REGISTRATION: The study was registered on Clinicaltrials.gov (Identifier NCT02780414). (Hypertension. 2022;79:1527–
1536. DOI: 10.1161/HYPERTENSIONAHA.122.19038.) Supplemental Material

•
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NOVELTY AND RELEVANCE
What Is New?
The ability to diagnose preeclampsia clinically is suboptimal. We sought to validate a novel multianalyte assay
and characterize its performance, when intended for use
as an aid to rule-out preeclampsia in pregnant individuals presenting between 280/7 to 366/7 weeks’ with preeclampsia-associated signs and symptoms.

What Is Relevant?
We validated a novel multi-analyte assay, which together
with the gestational age at sample collection, was

Nonstandard Abbreviations and Acronyms
HR
NPV
PD-L1

hazard ratio
negative predictive value
programmed death-ligand 1

P
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reeclampsia is a pregnancy-specific multisystem
disorder that affects 3% to 8% of pregnancies and
remains a leading cause of maternal and neonatal
morbidity and mortality.1,2 In the United States, it is the
third leading cause of maternal death, and worldwide
>70 thousand pregnant individuals die from preeclampsia-related causes each year.3 Recent data suggest that
preeclampsia contributes to racial and ethnic disparities,
with Black pregnant individuals 2 to 3× more likely to die
from preeclampsia compared with White individuals.4–6
Preeclampsia is traditionally diagnosed using the
criteria of hypertension along with proteinuria, or in
the absence of the latter, clinical symptoms, laboratory
abnormalities, or evidence of end-organ injury.1 Although
hypertension is a hallmark of preeclampsia, other hypertensive diseases also can occur during pregnancy and
must be differentiated in order for appropriate management to occur.1 Relying on clinical criteria is suboptimal
mainly because obtaining blood pressure and proteinuria
is subject to errors during collection (cuff size, position,
activity) and can fluctuate during the observation period,7,8
and relying on maternal symptoms may be problematic in
clinical practice because of their subjective nature.1,9,10
Because the specificity of these criteria is poor, pregnant
individuals in whom there is a suspicion for preeclampsia—but who may not actually have it—may be admitted
for monitoring and delivered prematurely.
While the pathogenesis of preeclampsia is not completely understood, it is thought to be related to impaired
early placental development,11–13 with associated
abnormalities in angiogenesis, endothelial and hypoxic
injury, oxidative stress, and inflammation.11,14–17 These
1516   July 2022

associated with the time to develop preeclampsia, had
moderate sensitivity and likelihood ratios, but a high negative predictive value for development of preeclampsia
within 7 days of enrollment.

Clinical/Pathophysiological Implications?
An assay of 8 biomarkers associated with angiogenic
imbalance, placental and trophoblast dysfunction, hypoxia,
and inflammation and immune regulation was validated
as an aid for physicians evaluating pregnant individuals
presenting with signs and symptoms of preeclampsia.

derangements ultimately lead to the clinical manifestations of the disease. Based on these pathophysiologic
pathways, a molecular assay was developed by Progenity,
Inc, intended to be used as an aid to rule-out preeclampsia.18 It includes 8 markers associated with angiogenic
imbalance (free and total placental growth factor, soluble
FMS-like tyrosine kinase-1, soluble endoglin), placental
and trophoblast dysfunction (fibroblast growth factor-21
and decorin), hypoxia (kidney injury molecule-1), and
inflammation and immune regulation (cluster of differentiation-274, or PD-L1 [programmed death-ligand 1]).18,19
The objective of this study was to validate the assay
and characterize its performance, when intended for use
as an aid to rule-out preeclampsia in pregnant individuals presenting with preeclampsia-associated signs and
symptoms between 280/7 and 366/7 weeks.

METHODS
De-identified data that support the findings of this study are
available from the sponsor upon reasonable request.

Study Population
Pregnant individuals 18 to 45 years old, with singleton, nonanomalous pregnancies between 280/7 weeks and 366/7
weeks gestation, who presented to triage, labor and delivery,
or an outpatient setting to rule-out preeclampsia were eligible
for enrollment in this multicenter prospective cohort study. We
excluded from enrollment those who had known fetal genetic
or major malformations; received dialysis; or multifetal gestations. Anomalous pregnancies were excluded as they may
affect pregnancy management and neonatal outcomes and
may be associated with genetic conditions that could impact
biomarkers levels. From those enrolled, we also excluded from
subsequent analysis those without a baseline sample, with a
sample that could not be analyzed, and with active cancer or
history of cancer with current status unknown, due to potential
effects of cancer on angiogenic biomarkers.
The trial was conducted at 20 academic and communitybased medical centers (Supplemental Material) across the
United States between 2016 and 2020. The Institutional
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Individuals presenting to rule-out preeclampsia (based on newonset elevated blood pressure if previously normotensive, or
worsening preexisting hypertension, new-onset proteinuria or
worsening of preexisting proteinuria, and other signs or symptoms that necessitated evaluation to rule out preeclampsia)
were evaluated according to the standard of care at individual
centers. Those not diagnosed with preeclampsia at the baseline evaluation were considered the main study cohort. In this
cohort, those who later developed preeclampsia before or at
delivery were classified as cases. The time (in days) from the
baseline sampling to diagnosis of preeclampsia was recorded.
Conversely, individuals who did not develop preeclampsia by
delivery represented the negative control group, and the time
from baseline sampling (in days) to either delivery or loss to
follow-up was recorded. On the contrary, eligible individuals
who were found to have preeclampsia at the time of baseline
evaluation (or within 24 hours of presentation if a 24-hour
urine was collected) were enrolled in a positive preeclampsia
control group.
Pregnancy management (eg, antenatal testing, management of preeclampsia, inpatient versus outpatient management, timing, and mode of delivery) was left to the discretion of
the treating clinician and performed per standard of care at the
respective participating institutions. All data were collected or
abstracted by research coordinators at the clinical centers. No
pregnant individual, care provider, or investigator had access
to the results of the biomarkers assay, which was run at the
completion of the study.

Study Outcome
The primary outcome for this study was the time to develop
preeclampsia, irrespective of disease severity, however, individuals who delivered without developing preeclampsia were censored at the time of their delivery. Preeclampsia was defined
according to the 2013 criteria set by the American College
of Obstetricians and Gynecologists,20 (the active guidelines
at the time the study was designed conducted; Supplemental
Material). Adjudication rules and process were set a priori
(Supplemental Material).

Sample Collection and Assay Development
Blood samples were collected at baseline and shipped to a
central laboratory facility (Progenity Inc; Ann Arbor, MI) where
they were analyzed in batch at the completion of the study. The
assay was developed by Progenity, Inc. (San Diego, CA) using
a separate cohort of individuals who were evaluated for preeclampsia.18,19 Details in the Supplemental Material.
For this study, the assay results are reported based on a
locked algorithm that includes the 8 biomarkers and gestational age at the time of blood draw. This algorithm was previously developed and optimized (data not included, but available
upon reasonable request from the sponsor), with a cutoff determined to be 0.0325 during a robust cut point determination

process aiming for a 90% sensitivity using a subset of the
training data. Individuals with values below 0.0325 are considered at reduced risk for preeclampsia and considered to have a
negative result. Conversely, those with values at or greater than
the cutoff are considered at increased risk for preeclampsia
events and reported to be at risk. There was no cutoff for individual biomarkers for classification decision-making, and the
dichotomization was determined solely based on the cutoff on
the model score generated by the algorithm. All laboratory staff
were masked to clinical outcomes.

Statistical Analysis
The study was originally designed to enroll up to 1541 individuals into the study cohort and 250 in the positive preeclampsia control group. This sample size was calculated using Cox
Proportional Hazards Regression, conservative estimates of
both performance (minimum hazard ratio [HR], 1.4) and prevalence for preeclampsia (20%), an R2 for other covariates of 0.10,
80% power, and alpha of 0.05. However, due to the higher than
anticipated incidence of preeclampsia, an unplanned one-time
subsequent sample size assessment indicated that a sample
size of at least 1036 in the study cohort would provide >90%
power at a HR of at least 1.6.
Out of 1730 individuals enrolled, samples from 70 of the
positive preeclampsia control group were randomly selected to
assist in the development and optimization of the algorithm and
are not part of this current analysis (Figure S1). The algorithm
was then locked. The sponsor divided the remaining 1660 individuals into a prevalidation set (n=356) and a validation set
(n=1,304; Figure S1). The 356 individuals in the prevalidation
set were selected randomly with the same gestational age distribution as the overall study and were used in an additional
unplanned assay robustness analysis, which did not lead to
changes in the algorithm.
Analyses reported in this article were performed by a statistician who had full access to the data and was independent
of the sponsor, and the results were reviewed for accuracy and
conformance to the prespecified statistical analysis plan by
one of the authors (M. Sarno) who had full access to all the
data in the study and takes responsibility for the integrity of the
conducted data analyses. Statistical analyses were performed
using JMPro 16.0 (SAS, Cary, NC).
Data were reported using descriptive statistics with
mean and SD or median and interquartile range for continuous measurements and number (%) for categorical variables.
Continuous variables were compared using Wilcoxon rank-sum
and categorical variables using the χ2 or Fisher exact tests, as
appropriate. The primary analysis was based on Cox proportional hazard regression and reported a HR with its associated
2-sided Wald 95% CI. The model employed a 2-group timeto-event analysis that compared the days to a preeclampsia
diagnosis between individuals with at risk and negative test
results. We calculated the HR for the test to indicate the hazard
of preeclampsia in individuals with an at-risk test result compared with the hazard of preeclampsia in those with a negative
test result using the time to develop preeclampsia or delivery,
whichever occurs first. Individuals who did not develop preeclampsia were censored at delivery or if lost to follow-up. The
prespecified multivariate Cox regression model for the primary
analysis adjusted for age (years, continuous), race and ethnicity
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(self-reported), gestational age at enrollment (weeks, continuous), body mass index (kg/m2, continuous), prior history of preeclampsia, and history of diabetes.
Performance metrics including sensitivity, specificity, positive predictive value, negative predictive value (NPV), positive
likelihood ratio, negative likelihood ratio, and accuracy were calculated along with their associated 2-sided 95% CIs. NPV and
positive predictive value are reported using the study population prevalence as well as theorized population prevalences of
2.7%, 10%, and 20% to compare performance across studies
using Bayes Rule. In addition, we estimated the false negative
rate of the assay in a cross-sectional manner using the positive
preeclampsia control group. Performance analyses in the study
cohort were also performed to assess the ability of the assay
to rule out preeclampsia for 7 and 14 days. For this analysis,
individuals were divided into those who developed the outcome
(preeclampsia case within the rule-out window; positive status)
and everyone else (those who did not develop preeclampsia or
developed preeclampsia outside of the rule-out window; negative status). Additional prespecified analyses were performed
for those who developed the outcome overall and in the 7- and
14-day rule-out window but who delivered <37 weeks, using
the clinical center’s diagnosis of preeclampsia (n=1042), and
for individuals who were enrolled between 28 and 35 weeks’
gestation. The analysis using the clinical center’s diagnosis of
preeclampsia represents the real-word performance of the
assay. Post hoc analyses for added benefit, including a computation of the Net Reclassification Improvement,21 were also
performed following unblinding and completion of all prespecified statistical analyses (Supplemental Materials).
All statistical tests were 2-tailed and performed at the 5%
significance level.

RESULTS
Of 1304 individuals, 117 were excluded (112 for no
usable samples and 5 for active cancer or history of
cancer with current status unknown), leaving 1042 individuals in the study cohort and 145 in the positive preeclampsia control group. In addition, 6 individuals from
the cohort were excluded due to inability to determine
the primary outcome by the adjudication committee

(Figure 1). The demographic and clinical characteristics
of the positive preeclampsia control group (n=145) are
summarized in Table S1.
Baseline characteristics of the study cohort (n=1036)
are summarized in Table S2. Individuals were enrolled
at 33.6±2.4 weeks gestation, most commonly for newonset hypertension (50% in the cohort). The cohort
was diverse with 30.9% self-identified as non-Hispanic
Black. Moreover, the cohort represented a high-risk
population with 35.5% being nulliparous, 30.5% having
a history of preeclampsia, 36.3% chronic hypertension,
and 11.4% pregestational diabetes. Maternal and neonatal outcomes of study cohort participants overall and
then of preeclampsia cases and negative control group
are summarized in Table 1 and demonstrate that cases
were more likely to have worse maternal and neonatal
outcomes compared with the negative control group.
Using the final adjudicated diagnoses, the overall rate
of preeclampsia in the study cohort was 30.3% (95% CI,
27.6%–33.2%), and the median (5th–95th percentiles)
time to develop preeclampsia was 51 (47–65) days.
The concordance in preeclampsia diagnosis between
the clinical sites and the adjudication committee was
94.6%. Figure 2 represents the survival curve plotting the proportion of individuals without preeclampsia
diagnosis by assay status (at-risk or negative). Overall,
the median (5th–95th percentiles) time to develop preeclampsia was 23 (20–26) days for those with at-risk
assay result compared with 76 (65–incalculable) days
for those with negative assay test result (P<0.0001).
The association between the test status and time to
develop preeclampsia was assessed with the univariable
Cox modeling with a univariable HR of 4.65 (95% CI,
3.60–6.00; P<0.0001). The primary model which a priori
adjusted for age, gestational age at enrollment, non-Hispanic Black race/ethnicity, body mass index, diabetes,
and history of preeclampsia, demonstrated the adjusted
HR was 4.81 (95% CI, 3.69–6.27; P<0.0001), indicating that the assay is associated with the time to develop
preeclampsia. In other models adjusting for gestational

Figure 1. Study flow chart.
1518   July 2022
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Study cohort
(n=1036)

Preeclampsia
cases (n=314)

Negative control
(n=722)

P value No.

Preeclampsia per adjudication committee*

314 (30.3)

314 (100)

0 (0.0)

<0.0001

 Preeclampsia with severe features per adjudication committee

239 (23.1)

239 (76.1)

0 (0.0)

<0.0001

315 (30.4)

297 (94.6)

18 (2.5)

<0.0001

Outcome
Maternal outcomes

Preeclampsia per site (n=1042)
HELLP syndrome

1 (0.1)

1 (0.3)

0 (0.0)

0.30

Placental abruption

6 (0.6)

2 (0.6)

4 (0.6)

1

Venous thromboembolic disease

1 (0.1)

0 (0.0)

1 (0.1)

1

Transfusion of blood products

12 (1.2)

3 (1.0)

9 (1.2)

1

Maternal death

1 (0.1)

1 (0.3)

0 (0.0)

0.30

Postpartum hemorrhage

45 (4.3)

13 (4.1)

32 (4.4)

1

Cesarean delivery

501 (48.4)

170 (54.1)

331 (45.8)

0.01

Neonatal outcomes
GA at delivery

36.8±2.0

35.7±2.0

37.3±1.8

<0.0001

Birth weight, g

2839±641

2591±654

2947±605

<0.0001

SGA

111 (10.7)

37 (11.8)

74 (10.3)

0.51

Preterm (<37 wk' GA)

391 (37.7)

215 (68.5)

176 (24.4)

<0.0001

Intrauterine fetal demise

3 (0.3)

2 (0.6)

1 (0.1)

0.22

Admission to neonatal intensive care unit

391 (37.7)

183 (58.3)

208 (28.8)

<0.0001

NICU visit ≥7 days

226 (21.8)

117 (37.3)

109 (15.1)

<0.0001

Respiratory distress syndrome

158 (15.3)

75 (23.9)

83 (11.5)

<0.0001
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Necrotizing enterocolitis

1 (0.1)

0 (0.0)

1 (0.1)

1

Positive culture neonatal sepsis

2 (0.2)

1 (0.3)

1 (0.1)

0.51

Intraventricular hemorrhage

1 (0.1)

1 (0.3)

0 (0.0)

0.30

Data are reported as median (IQR) or n (%). There were no cases of eclampsia, stroke, or neonatal death. GA indicates gestational
age; HELLP, hemolysis, elevated liver enzymes and low platelets syndrome; IQR, interquartile range; NICU, neonatal intensive care unit;
and SGA, small for GA.
*Preeclampsia as determined by adjudication committee.

age at enrollment and body mass index with or without
race, the association remained similar (Table S3). No significant difference in the model’s observed associations
was demonstrated using the outcome of preeclampsia as
determined by clinical centers (adjusted HR, 5.18 [95%
CI, 3.97–6.75]) instead of by the adjudication committee.
Among the 145 individuals in the positive preeclampsia
cohort, the false negative rate of the assay was 25.5%
(19.1%–33.2%).
Table 2 summarizes the performance metrics of the
assay. For the outcome of preeclampsia within 7 days of
enrollment, the incidence of preeclampsia was 10.2%
(95% CI, 8.5%–12.2%), and the cumulative percentage
of participants who did not develop preeclampsia was
significantly higher in the negative assay test compared
with the at-risk test group (adjusted HR, 3.84 [95% CI,
2.42–6.09]; P<0.0001), with a sensitivity 76.4% (95%
CI, 67.5%–83.5%), specificity 51.5% (48.3%–54.7%),
negative likelihood ratio 0.46 (0.32–0.65), and a NPV
95.0% (95% CI, 92.8%–96.6%). For an outcome of
preeclampsia at any time in pregnancy, the assay had
a sensitivity of 69.4% (95% CI, 64.1%–74.3%) and a

NPV 81.0% (95% CI, 77.3%–84.1%) with an accuracy
of 60.4% (95% CI, 57.4%–63.4%). Sensitivity, NPV, and
negative likelihood ratio slightly improved for those who
ultimately delivered <37 weeks. Assay performance
was overall similar when using preeclampsia as determined by the clinical centers (Table 3). Performance
slightly improved for individuals enrolled between 28
and 35 weeks’ gestation (Table S4). Test accuracy for
the entire cohort is reported in Table S4. Test heterogeneity for individual sites (Supplemental Materials) was
demonstrated graphically using a forest plot (Figure S2)
with the results indicating that test accuracy was similar
across the study sites.
Lastly, post hoc added benefit analyses (methods in Supplemental Materials)21,22 indicated significant improvement of predictive power by including the
assay in addition to clinical covariates. The log-likelihood
analysis indicated accuracy improvement (P<0.0001),
whereas the comparison of receiver operating curve
curves indicated an approximate 11% increase in area
under the curve in the primary model (area under the
curve, 0.733 [95% CI, 0.700–0.766]) as compared with
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Figure 2. Survival curves (with 95% confidence margin) plotting the proportion of individuals without preeclampsia diagnosis vs
the time to develop preeclampsia (in days), by assay status (at risk red or negative blue).
Those who did not develop preeclampsia were censored at delivery or if lost to follow-up.
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the model using clinical covariates (area under the curve,
0.659 [95% CI, 0.623–0.695]; P<0.0001). (Figure 3)
Last, the net reclassification index calculation resulted in
an 10.98% (95% CI, 3.77%–8.19%) net improvement in
predictive categorization (P=0.003).

DISCUSSION
Using a large cohort of high-risk pregnant individuals presenting with preeclampsia associated signs and
symptoms between 280/7 and 366/7 weeks, we validated
a novel multi-analyte assay, which together with the gestational age at sample collection, was demonstrated to
be associated with the time to develop preeclampsia and
had a net reclassification improvement of ≈11%. The
assay demonstrated a moderate sensitivity and likelihood
ratios, but a high NPV for development of preeclampsia within 7 days after enrollment. Test performance was
improved for individuals enrolled between 28 and 35
weeks and for those who developed preeclampsia within
7 days of enrollment and delivered <37 weeks.
The Cox regression model remained highly significant
after adjusting for multiple covariates suggesting the
strength and independence of the assay in its association with preeclampsia. The inclusion of race as a socially
constructed variable was a priori planned in the multivariable analysis. Also, the algorithm to assess the risk status
of preeclampsia, including the determination of the cutoff,
was done without the inclusion of race, to avoid perpetuating health disparities, as we are cognizant of the racial
1520   July 2022

disparities in preeclampsia rates and morbidities, due to
social drivers, in the United States. The outcomes of 6
individuals could not be adjudicated by the adjudication
committee due to missing data and inability to obtain the
data from the sites. However, these 6 individuals were
included in the analysis using preeclampsia diagnosis as
determined by the clinical center, and there was excellent
concordance (94.6%) between preeclampsia diagnosed
by providers at the sites and preeclampsia confirmed by
the adjudication committee. Lastly, while other studies
evaluating preeclampsia biomarkers assays focused on
PlGF or sFlt-1/PlGF, the current assay included eight
biomarkers associated with pathophysiologic pathways
of preeclampsia including angiogenic imbalance (free
and total placental growth factor, soluble FMS-like
tyrosine kinase-1, soluble endoglin), placental and trophoblast dysfunction (fibroblast growth factor-21 and
decorin), hypoxia (kidney injury molecule 1), and inflammation and immune regulation (cluster of differentiation-274 or programmed death-ligand-1).18,19
This is one of the larger studies evaluating an assay
as an aid to rule out preeclampsia in at-risk pregnant
individuals presenting with signs and symptoms. In a
prospective multicenter study from the United Kingdom,
Chappell et al23 demonstrated that, among individuals
with suspected preeclampsia enrolled between 20 and
35 weeks, a low plasma PlGF concentration (<5th percentile for gestation; <100 pg/mL) had a high sensitivity
(96% [95% CI, 89%–99%]) and a high NPV (98% [95%
CI, 93%–99.5%]) for the development of preeclampsia

Hypertension. 2022;79:1527–1536. DOI: 10.1161/HYPERTENSIONAHA.122.19038
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Outcome

aHR*

Prevalence

Sensitivity

Specificity

PPV

NPV

PLR

NLR

Accuracy†

Preeclampsia within
7 days

3.84
(2.42–6.09)

10.2%
(8.5–12.2)

76.4%
(67.5–83.5)

51.5%
(48.3–54.7)

15.2%
(12.4–18.5)

95.0%
(92.8–96.6)

1.58
(1.39–1.79)

0.46
(0.32–0.65)

54.1%
(51.0–57.1)

Preeclampsia within
14 days

4.20
(2.93–6.01)

17.0%
(14.8–19.4)

76.7%
(69.9–82.3)

53.8%
(50.5–57.1)

25.4%
(21.9–29.2)

91.9%
(89.1–93.9)

1.66
(1.49–1.85)

0.43
(0.33–0.57)

57.7%
(54.7–60.7)

Preeclampsia determined by adjudication
committee (n=1036)

4.81
(3.69–6.27)

30.3%
(27.6–33.2)

69.4%
(64.1–74.3)

56.5%
(52.9–60.1)

41.0%
(36.9–45.2)

81.0%
(77.3–84.1)

1.60
(1.43–1.78)

0.54
(0.45–0.65)

60.4%
(57.4–63.4)

Preeclampsia determined by clinical site
(n=1042)

5.18
(3.97–6.75)

30.2 %
(27.5–33.1)

70.2%
(64.9–74.9)

56.7%
(53.0–60.2)

41.2%
(37.1–45.4)

81.4%
(77.8–84.6)

1.62
(1.45–1.81)

0.53
(0.44–0.63)

60.7%
(57.7–63.7)

Preeclampsia and
delivery <37 wk‡

5.42
(3.91–7.51)

20.8%
(18.5–23.4)

74.1%
(67.8–79.5)

54.6%
(51.2–58.0)

30.1%
(26.3–34.1)

88.9%
(85.8–91.3)

1.63
(1.46–1.82)

0.48
(0.38–0.60)

58.7%
(55.7–61.6)

Preeclampsia within
7 days and delivery
<37 wk‡

6.02
(3.29–11.04)

7.7%
(6.2–9.5)

83.8%
(74.2–90.3)

51.4%
(48.2–54.5)

12.6%
(10.0–15.7)

97.4%
(95.6–98.5)

1.72
(1.53–1.93)

0.32
(0.19–0.52)

53.9%
(50.8–56.9)

Preeclampsia within
14 days and delivery
<37 wk‡

5.53
(3.52–8.70)

12.6%
(10.8–14.8)

81.7%
(74.2–87.4)

53.0%
(49.8–56.3)

20.1%
(16.9–23.7)

95.2%
(93.0–96.8)

1.74
(1.56–1.94)

0.35
(0.24–0.50)

56.7%
(53.6–59.6)

Data reported with (95% CI). aHR indicates adjusted hazard ratio; BMI, body mass index; GA, gestational age; NLR, negative likelihood ratio; NPV, negative predictive
value; PPV, positive predictive value; and PLR, positive likelihood ratio.
*Primary model adjusted for maternal age, BMI, GA at enrollment, race, diabetes, history of preeclampsia.
†Methods to determine test accuracy are included in Supplemental Materials.
‡Delivery within rule out window or 37 wk whichever is later.
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requiring delivery within 14 days. In the Preeclampsia Triage by Rapid Assay Trial, which included individuals with
signs or symptoms of preeclampsia between 20 and 35
weeks’ gestation, a low PlGF (≤100 pg/mL) had have
a HR of 7.17 (95% CI, 5.08–10.13) for time to delivery,
92.5% specificity and 90.3% NPV for preeclampsia and
delivery within 14 days, however that study had a prevalence of preeclampsia of 71.4%.24 Our assay had excellent NPV (95.2% [95% CI, 93.0%–96.8%]), but lower
sensitivity, in ruling out preeclampsia within 14 days
when the individual delivered before 37 weeks. Zeisler et
al25 showed that in individuals between 240/7 and 366/7
weeks’, an sFlt-1:PlGF ratio cutoff of 38, has a NPV of
99.3% (95% CI, 97.9%–99.9%) for preeclampsia within

1 week of presentation. However, the prevalence of preeclampsia in that cohort was extremely low at 2.7%, indicating a low-risk population. When setting the prevalence
at 2.7% (similar to the Zeisler cohort), our assay achieved
a NPV of 98.5% (95% CI, 97.0%–99.3%) for preeclampsia at any time in pregnancy (Table S5). Moreover, our
assay had a NPV of 95.0% (95% CI, 92.8%–96.6%) to
rule out preeclampsia within 1 week, with a prevalence
of preeclampsia of 10.2%. When evaluating the entire
cohort, the prevalence of preeclampsia in Zeisler’s cohort
was 17.8%, lower than the rate of 30.3% in our cohort,
which is more representative of a high-risk US population. However, among the 145 individuals in the positive
preeclampsia cohort in our study, the false negative rate

Table 3. Performance (95% CI) Test Characteristics for Various Outcomes Based on Clinical Centers Assessments (n=1042)
Outcome

aHR*

Prevalence

Sensitivity

Specificity

PPV

NPV

PLR

NLR

Accuracy

Preeclampsia within 7
days

4.81
(2.87–8.07)

9.0%
(7.4–10.9)

79.8%
(70.6–86.7)

51.4%
(48.2–54.5)

14.0%
(11.3–17.2)

96.2%
(94.2–97.6)

1.64
(1.45–1.85)

0.39
(0.26–0.59)

53.9%
(50.9–56.9)

Preeclampsia within 14
days

5.11
(3.47–7.53)

16.0%
(13.9–18.4)

79.6%
(72.9–85.0)

53.9%
(50.6–57.2)

24.8%
(21.3–28.6)

93.3%
(90.8-95.2)

1.73
(1.56–1.92)

0.38
(0.28–0.51)

58.1%
(55.0–61.0)

Preeclampsia before or
at delivery

5.18
(3.97–6.75)

30.2 %
(27.5–33.1)

70.2%
(64.9–74.9)

56.7%
(53.0–60.2)

41.2%
(37.1–45.4)

81.4%
(77.8–84.6)

1.62
(1.45–1.81)

0.53
(0.44–0.63)

60.7%
(57.7–63.7)

Preeclampsia and delivery <37 wk†

5.61
(4.06–7.76)

21.1%
(18.7–23.7)

74.1%
(67.9–79.4)

54.6%
(51.2–58.0)

30.4%
(26.7–34.4)

88.7%
(85.7–91.2)

1.63
(1.47–1.82)

0.47
(0.38–0.60)

58.7%
(55.7–61.7)

Preeclampsia within 7
days and delivery <37 wk†

6.37
(3.40–11.94)

7.4%
(6.0–9.1)

84.4%
(74.7–90.9)

51.2%
(48.0–54.3)

12.1%
(9.6–15.2)

97.6%
(95.9–98.6)

1.73
(1.54–1.94)

0.30
(0.18–0.51)

53.6%
(50.6–56.7)

Preeclampsia within 14
days and delivery <37 wk†

6.18
(3.87–9.87)

12.6%
(10.7–14.7)

83.2%
(75.9–88.6)

53.1%
(49.9–56.3)

20.3%
(17.1–23.9)

95.7%
(93.5–97.1)

1.78
(1.60–1.97)

0.32
(0.22–0.47)

56.9%
(53.9–59.9)

Data reported with (95% CI). aHR indicates adjusted hazard ratio; BMI, body mass index; GA, gestational age; NLR, negative likelihood ratio; NPV, negative predictive
value; PPV, positive predictive value; and PLR, positive likelihood ratio.
*Primary model adjusted for maternal age, BMI, GA at enrollment, race, diabetes, history of preeclampsia.
†Delivery within rule out window or 37 wk whichever is later.
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Table 2. Performance (95% CI) Test Characteristics for Various Outcomes Based on Adjudication Committee Assessments and
the Prespecified Cutoff
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Figure 3. Receiver-operating
characteristic curves (with 95%
confidence margin) of the predictive
probabilities of the models with only
clinical covariates and the model
including clinical covariates and the
assay.
AUC indicates area under the curve.
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of the assay was 25.5% (19.1%–33.2%). This is higher
than the other assays and should be considered in any
future study evaluating the clinical utility of the assay and
its incorporation in clinical practice.
With the limitations of clinical parameters in diagnosing or ruling out preeclampsia,1 a need exists to develop
laboratory assays that can assist providers and complement clinical assessments. The utility of such assays
has been shown in a cluster stepped-wedge trial from
the United Kingdom which demonstrated that the availability of a rapid PlGF assay results reduced the time
to preeclampsia confirmation in individuals presenting
with suspected preeclampsia and was associated with a
lower frequency of maternal adverse outcomes.26
This study was designed to collect specimens for the
validation of a rule-out assay and was neither developed
to be a diagnostic test or function as a clinical utility study.
Thus, further studies should be conducted to determine
the clinical utility of this assay vis-a-vis the current model
of care in the United States especially with a net reclassification improvement of ≈11%, its ability to reduce
time to diagnosis of preeclampsia, or improve clinical
outcomes. In view of the results, future studies should
also focus on the utility of the 7-day rule out window for
the assay, and the interpretation of a negative or at risk
test in high-risk individuals in the context of clinical standards of care, especially with a high false negative rate
of 25.5%. In addition, we did not perform a cost analysis or evaluate whether incorporation of the assay would
lead to reduced utilization of health care resources or
improved outcomes.
Strengths of this study include enrollment at 20
clinical study sites of a large geographically and racially
diverse cohort in the United States. Testing of the samples was performed in a blinded manner at a central laboratory ensuring rigorous quality control. Analyses were
1522   July 2022

performed using the final adjudicated preeclampsia diagnosis and the clinical center’s diagnosis of preeclampsia.
Despite the large cohort, we were limited in our ability to assess meaningfully whether the assay performs
differently in subgroups of the population (eg, those
with medical co-morbidities). The primary outcome of
the study was the time to develop preeclampsia irrespective of its severity, therefore the performance of
the test as an aid in the diagnosis of preeclampsia with
severe features alone is not available. However, 73% of
preeclampsia cases in the cohort had severe features.
In addition, the study was not powered to detect differences in rates of individual clinical outcomes such as placental abruption or postpartum hemorrhage. The rates of
these and other outcomes are similar to what is reported
in prior similar trials and what is expected in a high-risk
cohort.23,25–27 Although study enrollment was conducted
between 2016 and 2020, the specimens were banked,
and the analysis was not complete until July 2021 while
the laboratory was developing and optimizing the assay
and laboratory processes. The study enrolled a larger
number than were in the final analysis, since samples
from 70 individuals from the positive preeclampsia control group were used to optimize the assay, and an additional 365 from the study cohort were later used by the
sponsor in a prevalidation cohort to ensure the robustness of the algorithm in divergent populations; both originally unplanned analyses. Moreover, the incorporation of
this assay in clinical flow should be developed further,
and a point-of-care rapid test may enhance its clinical
value. The individual analytes were not analyzed separately, and their individual performance was not available.
Therefore, we are not able to compare their individual
performance s vis-à-vis the composite multianalyte assay
or known published literature on performance of sFlt1
and PlGF measured on other platforms.23,25,26 We cannot
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Conclusions
Using a large cohort of high-risk pregnant individuals,
we have confirmed that a novel multianalyte assay is
associated with the time to develop preeclampsia and
has a moderate sensitivity and negative likelihood ratio
but high NPV when assessed as an aid to rule out preeclampsia within 7 days of enrollment.

Perspectives

Downloaded from http://ahajournals.org by on September 14, 2022

Preeclampsia is a pregnancy-specific multisystem disorder that affects 3% to 8% of pregnancies and remains
a leading cause of maternal and neonatal morbidity and
mortality, with significant racial and ethnic disparities. Relying on clinical criteria to diagnose preeclampsia is suboptimal because they are subjective, may be subject to errors
during collection, and can fluctuate during the observation period. Because the specificity of these criteria is
poor, pregnant individuals in whom there is a suspicion for
preeclampsia—but who may not actually have it—may be
admitted for monitoring and delivered prematurely. A significant need exists to develop laboratory assays that can
assist providers and complement clinical assessments.
This study validated the performance of a multi-analyte
test among pregnant people presenting with signs and
symptoms of preeclampsia between 280/7 and 366/7 weeks’
gestation and demonstrated that the assay was associated
with the time to develop the disease and has moderate
sensitivity and likelihood ratios, but a high NPV for development of preeclampsia within 7 days after enrollment.
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